Can-Fite Biopharma Ltd (CANF)
CANF trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1536196/000121390026034447/0001213900-26-034447-index.htm. Net income: SEC 20-F (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | CANF on NYSE |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Israel |
| IPO year | Not reported by the screener |
| SEC CIK | 0001536196 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | Israel |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $405K |
| Net income | -$9.8M |
| Operating income | -$9.9M |
| Net margin | -2426.7% |
| Operating margin | -2456.8% |
| Revenue growth | -39.9% |
| Cash | $5.5M |
| Total assets | $9.5M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 11.7× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "Evaluation of Substantial Doubt Raised In performing the first step of the evaluation, the Company concluded that the following conditions raised substantial doubt about its ability to continue as a going concern: - History of net losses of $ 9,828 , $ 7,880 and $ 7,634 for the years ended December 31, 2025, 2024 and 2023, respectively." | 20-F 2026-03-26 |
| Cash and burn | $5.5M cash; operating cash flow -$2.2M a quarter. | Report 2025-12-31 |
| Shares outstanding | No cover-page share count in XBRL | Cover page 2025-12-31 |
| Reverse splits, 3 years | 1; latest 1-for-20 on 2026-01-05 | Source 2026-01-05 |
| Shelf and offerings, 12 months | 3 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-09-25 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Kost Forer Gabbay & Kasierer, Tel Aviv, Israel | PCAOB Form AP 2026-04-25 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | $405K | -$9.8M | -$8.9M | $5.5M | No debt tags | $405K | 20-F 2026-03-26 |
| FY 2024 2024-12-31 | $674K | -$7.9M | -$7.6M | $4.8M | No debt tags | $674K | 20-F 2026-03-26 |
| FY 2023 2023-12-31 | $743K | -$7.6M | -$8.4M | $4.3M | No debt tags | $743K | 20-F 2026-03-26 |
| FY 2022 2022-12-31 | $810K | -$10.2M | -$10.8M | $3.0M | No debt tags | $810K | 20-F 2025-04-14 |
| FY 2021 2021-12-31 | $853K | -$12.6M | -$9.9M | $4.4M | No debt tags | $853K | 20-F 2023-03-30 |
| FY 2020 2020-12-31 | $763K | -$14.4M | -$12.1M | $8.3M | No debt tags | $763K | 20-F 2023-03-30 |
| FY 2019 2019-12-31 | $2.0M | -$12.6M | -$11.1M | $2.7M | No debt tags | $2.0M | 20-F 2022-03-24 |
| FY 2018 2018-12-31 | $3.8M | -$6.6M | -$4.2M | $3.6M | No debt tags | $3.8M | 20-F 2021-03-25 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document PROSPECTUS | 424B3 | 2026-10-09 |
| Latest annual report ANNUAL REPORT | 20-F | 2026-03-26 |
| Latest quarterly / interim REPORT OF FOREIGN PRIVATE ISSUER | 6-K | 2026-11-12 |
Source: SEC EDGAR submissions feed, 867 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -12.3% |
| 1 month | -27.2% |
| 3 months | -58.2% |
| Year to date | -64.5% |
| 1 year | -80.8% |
| From 52-week high | -81.8% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| SKYE | Skye Bioscience Inc. | $1.06 | -2.29% | $4.7M |
| PCSA | Processa Pharmaceuticals Inc. | $1.72 | -7.53% | $4.8M |
| PULM | Pulmatrix Inc. | $1.33 | +2.31% | $4.9M |
| SCNX | Scienture Holdings Inc. | $2.99 | +3.10% | $4.9M |
| CVKD | Cadrenal Therapeutics Inc. | $1.40 | -7.28% | $5.0M |
| NCNA | NuCana plc American Depositary Share | $0.8631 | -7.46% | $4.4M |
| CNSP | CNS Pharmaceuticals Inc. | $3.48 | +20.42% | $5.1M |
| KPRX | Kiora Pharmaceuticals Inc. | $0.9820 | -20.16% | $4.3M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier